Wai Yuen Tong Medicine Holdings Limited (HKG:0897)

HKG:0897 Cash Flow Statement

Financials in millions HKD. Fiscal year is April - March.

Operating Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	3.99	7.1	-15.36	-20.52	-108.91
Depreciation & Amortization	84.15	90.48	111.15	113.05	107.8
Loss (Gain) From Sale of Assets	-0.03	-15.17	-26.44	7.5	-1.81
Asset Writedown & Restructuring Costs	11.47	-14.2	153.98	24.78	80.62
Loss (Gain) From Sale of Investments	-1.25	21.1	13.98	22.12	86.03
Loss (Gain) on Equity Investments	-1.57	-1.05	-2.53	-2.95	-1.57
Stock-Based Compensation	-	-	3.84	4.65	1.14
Other Operating Activities	-18.2	-13.36	-31.51	61.49	65.5
Change in Accounts Receivable	8.27	-13.49	-13.14	-14	-14.43
Change in Inventory	10.5	65.7	-45.96	94.91	303.02
Change in Accounts Payable	7.74	-4.94	-2.29	-3.14	12.21
Change in Unearned Revenue	-5.29	-2.52	-0.79	-49	-372.94
Change in Other Net Operating Assets	-29.35	-17.33	-24.8	-64.51	12.45
Operating Cash Flow	70.43	102.32	191.69	168.34	169.11
Operating Cash Flow Growth	-31.16%	-46.62%	13.87%	-0.46%	-59.01%

Investing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-13.49	-27.16	-34.65	-33.45	-26.04
Sale of Property, Plant & Equipment	19.18	62.07	86.82	2.6	0.88
Cash Acquisitions	-	-	-78.12	-	-
Divestitures	-	-	165.02	46.65	-
Sale (Purchase) of Real Estate	-	69.83	-7.9	3.7	-7.59
Investment in Securities	-	42.06	69.26	-3.38	20.23
Other Investing Activities	45.45	49.08	-183.34	1.3	22.37
Investing Cash Flow	71.13	280.89	-84.62	19.25	6.47

Financing Activities

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Long-Term Debt Issued	134.94	60.08	818.97	952.2	589.87
Long-Term Debt Repaid	-255.56	-233.7	-1,117	-1,004	-679.51
Net Debt Issued (Repaid)	-120.62	-173.62	-297.69	-51.99	-89.64
Repurchase of Common Stock	-3.87	-11.8	-14.73	-9.96	-
Common Dividends Paid	-	-199.14	-	-	-
Other Financing Activities	-16.18	-21.13	-157.55	-96.96	-114.78
Financing Cash Flow	-140.67	-405.69	-469.97	-158.91	-204.41

Net Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	0.06	-0.17	-8.83	-12.12	31.75
Net Cash Flow	0.96	-22.65	-371.73	16.56	2.91

Free Cash Flow

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	56.94	75.16	157.04	134.89	143.07
Free Cash Flow Growth	-24.24%	-52.14%	16.42%	-5.72%	-59.48%
Free Cash Flow Margin	8.33%	10.08%	20.03%	18.64%	10.28%
Free Cash Flow Per Share	0.05	0.07	0.13	0.11	0.12
Levered Free Cash Flow	61.23	147.82	733.16	-5.57	22.41
Unlevered Free Cash Flow	72.23	165.41	758.65	12.87	82.22

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Interest Paid	16.18	25.51	139.82	86.35	58.46
Cash Income Tax Paid	1.27	0.88	34.64	53.06	81.87
Change in Working Capital	-8.13	27.41	-86.97	-35.75	-59.68

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 2, 2026

Data Sources Report a data error